Explore two analyses from BADBIR.
Latest analysis by the BADBIR group
See the independent publication which supports the position of Cosentyx as a first-line biologic in moderate to severe plaque psoriasis.1
This link will take you to the Wiley Online Library website, which is a non-Novartis website.
Analysis by Novartis using BADBIR data
See the Cosentyx data below demonstrating long-term effectiveness and drug survival.2
About the analysis by Novartis using BADBIR data
BADBIR evaluates the long-term safety and effectiveness of biologic treatments for psoriasis in the UK and ROI.2,3
What is BADBIR?
BADBIR is a prospective, longitudinal pharmacovigilance register assessing the long-term safety of biologics, conventional systemic therapies and small molecule immunomodulators for psoriasis.
- Adults enrolled from 01 January 2016 to 31 August 2018 (still ongoing)
- Only patients with at least one follow-up visit were included
1679 moderate to severe psoriasis patients treated with the licensed dose of Cosentyx. Of these:
- ~1/3 biologic-naïve patients (n=507)
- ~2/3 biologic-exposed patients (n=1172)
*Analysis by Novartis using BADBIR data. aPASI ≤3 reflects clear or almost clear skin, or a physician global assessment of 0/1.4
aPASI scores at 12 and 24 months were imputed using data recorded ±90 days of each time point. The fall in patient numbers between Years 1 and 2 reflects fewer patients being on treatment long enough to reach the 2-year time point.2
Adapted from Bewley A et al. 2019.2
Adult patients with moderate to severe plaque psoriasis treated with Cosentyx 300 mg enrolled from 01 January 2016 to 31 August 2018 with at least one follow-up visit evaluated were included in this Novartis analysis of the BADBIR registry. The n-numbers reflect those patients meeting each time point. BADBIR approved the statistical analysis plan used.2
aPASI, absolute Psoriasis Area Severity Index; BADBIR, British Association of Dermatologists Biologic and Immunomodulators Register; DMARD, disease-modifying anti-rheumatic drug; MTX, methotrexate; ROI, Republic of Ireland.
- Yiu ZZN et al. Br J Dermatol 2020; doi:10.1111/bjd.18981.
- Bewley A et al. Secukinumab 300 mg demonstrates high and sustained effectiveness in treating patients with moderate to severe plaque psoriasis: Real world evidence from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR). Poster presented at: the 6th Annual Practical Symposium; 8–11 August 2019; Beaver Creek, Colorado, USA.
- Burden AD et al. Br J Dermatol 2012;166(3):545–554.
- Amatore F et al. J Eur Acad Dermatol Venereol 2019;33:464–483.